Connor, Clark & Lunn Investment Management Ltd. Immunovant, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$28.9 Billion
Q3 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Immunovant, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 558,897 shares of IMVT stock, worth $15.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

558,897

Previous 448,515 24.61%

Holding current value

$15.4 Million

Previous $12.3 Million 24.62%

% of portfolio

0.05%

Previous 0.05%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	N/A	110,382 Added 24.61%	558,897 $15.4 Million
Q2 2025 Aug 07, 2025	BUY	N/A	84,286 Added 23.14%	448,515 $12.3 Million
Q1 2025 May 12, 2025	BUY	N/A	128,345 Added 54.41%	364,229 $10 Million
Q4 2024 Feb 10, 2025	BUY	N/A	54,085 Added 29.75%	235,884 $6.49 Million
Q3 2024 Nov 08, 2024	SELL	$27.51 - $27.51 $1.56 Million - $1.56 Million	-56,789 Reduced 23.8%	181,799 $5 Million

Q2 2024 Aug 09, 2024	BUY	$25.1 - $31.61 $2.36 Million - $2.98 Million	94,203 Added 65.24%	238,588 $6.3 Million
Q1 2024 May 09, 2024	SELL	$30.27 - $43.79 $177,230 - $256,390	-5,855 Reduced 3.9%	144,385 $4.67 Million
Q4 2023 Feb 09, 2024	SELL	$31.31 - $44.19 $3.04 Million - $4.28 Million	-96,942 Reduced 39.22%	150,240 $6.33 Million
Q3 2023 Nov 13, 2023	BUY	$18.55 - $39.96 $1.84 Million - $3.97 Million	99,378 Added 67.24%	247,182 $9.49 Million
Q2 2023 Aug 10, 2023	BUY	$14.2 - $23.75 $1.21 Million - $2.03 Million	85,421 Added 136.93%	147,804 $2.8 Million
Q1 2023 May 09, 2023	BUY	$15.27 - $19.72 $552,224 - $713,154	36,164 Added 137.93%	62,383 $967,000
Q4 2022 Feb 10, 2023	BUY	$6.59 - $17.75 $51,843 - $139,639	7,867 Added 42.87%	26,219 $465,000
Q3 2022 Nov 10, 2022	BUY	$3.93 - $6.37 $72,123 - $116,902	18,352 New	18,352 $102,000
Q2 2022 Aug 05, 2022	SELL	$3.38 - $5.65 $150,977 - $252,374	-44,668 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$5.06 - $8.77 $558,487 - $967,971	-110,373 Reduced 71.19%	44,668 $246,000
Q4 2021 Feb 10, 2022	BUY	$7.33 - $9.32 $564,336 - $717,546	76,990 Added 98.64%	155,041 $1.32 Million
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $547,137 - $887,439	78,051 New	78,051 $678,000

Others Institutions Holding IMVT

# of Institutions

214

Shares Held

81.1M

Call Options Held

597K

Put Options Held

704K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Immunovant, Inc. Transaction History